Whether Lebrasin (Daveco) has been included in medical insurance and the actual price after medical insurance reimbursement

Lemborexant () is a dual soporific receptor antagonist (DORA), mainly used to treat adult insomnia patients who have difficulty falling asleep or maintaining sleep. By antagonizing hypnosis-activated receptors (orexin-1 and orexin-2receptors) in the brain, Lebraxen can improve sleep quality and extend total sleep time, while having less impact on cognitive function and next-day wakefulness, making it an important choice for modern clinical insomnia treatment.

The original drug Lebrasant was launched in the United States in 2019 under the trade name Dayvigo, and was subsequently launched in Japan and some countries. Domestically, Lebrasyn has also been officially launched as an original drug, but it has not yet been included in the medical insurance system. Not being covered by medical insurance means that patients have to pay for it out of pocket, and long-term medication costs are high. They need to weigh their affordability and treatment needs.

According to the current market conditions, the overseas price of the Japanese version of Lebrasin’s original drug is about RMB 1,000, while the domestic price of the original drug may be slightly higher than this level. Since there are no generic drugs on the market yet, patients can only choose original drugs to obtain therapeutic effects, which also makes their prices relatively stable but the economic burden is heavy. When not covered by medical insurance, patients need to bear all drug costs during long-term treatment. Especially for chronic insomnia patients who require continuous medication, the cost pressure cannot be ignored.

Overall, Lebrasin has not yet been included in medical insurance in China, and patients still have to pay for it at their own expense. The actual price is slightly higher than overseas. Although the drug is effective in improving sleep quality and reducing nighttime awakenings, the high cost may affect some patients' willingness to continue using it. In the future, if the negotiations for inclusion in medical insurance are successful or domestic generic drugs are launched, the accessibility and economics of leborexan are expected to be further improved, providing more patients with insomnia with a safe, effective and affordable treatment option.

Reference link:https://www.drugs.com